$NVO News and Market Events
Every $NVO story Market Flux has tracked.
- Last 7 days
- 1 story
- Previous 7 days
- 2 stories
- Latest story
- Related topics
- Healthcare, Earnings, Analyst Ratings
- Top Story
FDA Orders Vision-Loss Warning Labels on GLP-1 Drugs Including Ozempic and Zepbound
The U.S. Food and Drug Administration on November 9 ordered the makers of blockbuster GLP-1 drugs to add warnings about a rare but potentially permanent eye condition to their product…
- Unusual Volume
Novo Nordisk Beats Q3 Estimates and Raises Full-Year Guidance as Wegovy Pill Surpasses Forecasts
Novo Nordisk posted a strong third quarter on November 4, with adjusted sales of DKK 79.20 billion beating the DKK 73.55 billion consensus estimate and adjusted net income of DKK 25.60…
- Market Flux Event
Novo Nordisk Beats Q3 Forecasts on Obesity Drug Surge and Raises Full-Year 2026 Guidance
Novo Nordisk posted stronger-than-expected third-quarter results on November 4, with adjusted sales of DKK 79.20 billion beating the DKK 73.55 billion estimate, and raised its full-year…
- Market Flux Event
Eli Lilly's Retatrutide Delivers More Than Double the Weight Loss of Ozempic in Phase 3 Diabetes Trial
Eli Lilly's investigational drug retatrutide produced more than twice the average weight loss of Novo Nordisk's Ozempic at its highest approved dose in an 80-week Phase 3 trial enrolling…
- Top Mover
Eli Lilly Hits All-Time High Above $1,293 as Goldman Sachs Raises Price Target to $1,413
Eli Lilly shares surged roughly 4-5% on October 20 to a record high of $1,293.11, with the stock adding approximately $41 billion in market value in a single session and pushing the…
- Market Flux Event
BioNTech mRNA Cancer Drug Fails First Primary Endpoint in Head and Neck Trial, Stock Slides
BioNTech's mRNA-based cancer therapy missed the first of two dual primary endpoints in a mid-stage clinical trial targeting head and neck cancer, the company disclosed on October 13. The…
- Top Story
WHO Sidelines GLP-1 Drugs for Child Obesity as PepsiCo Faces Investor Pressure Over Same Threat
The World Health Organization released its first-ever guidelines on childhood obesity on October 7, endorsing lifestyle interventions such as diet and physical activity while stopping short…
- Market Flux Event
Eli Lilly Says Zepbound Outperforms Higher-Dose Wegovy in New Weight Loss Data, and Touts Foundayo Edge Over Ozempic Pill
Eli Lilly released new clinical data on September 29 showing that its obesity drug Zepbound delivered greater weight loss than a higher-dose version of Novo Nordisk's Wegovy, extending…
- Unusual Volume
Novo Nordisk Stock Falls Up to 7.4% as 2030 Strategy and $23 Billion Pipeline Target Disappoint Investors
Novo Nordisk shares plunged as much as 7.4% on Monday after CEO Mike Doustdar used a Capital Markets Day in London to lay out a long-term growth strategy that failed to calm investor…
- Market Flux Event
FDA Accepts Cogent Biosciences NDA for Bezuclastinib as Novo Nordisk Rebrands Amid Lilly Competition
Cogent Biosciences secured a key regulatory milestone as the FDA accepted its New Drug Application for bezuclastinib in patients with Advanced Systemic Mastocytosis, assigning a PDUFA…
- Market Flux Event
Eli Lilly Wins European Approval for Weight Loss Pill Foundayo as BMY Scores FDA Nod for Myeloma Drug
Eli Lilly secured the first European regulatory approval for its oral weight loss pill Foundayo in the United Kingdom, intensifying a direct battle with Novo Nordisk, whose oral Wegovy was…
- Top Mover
Eli Lilly's Oral Weight-Loss Pill Foundayo Wins First European Approval in the UK
Britain's Medicines and Healthcare products Regulatory Agency approved Eli Lilly's oral GLP-1 pill orforglipron, branded Foundayo, on August 10, making the UK the first European country to…
- Market Flux Event
Eli Lilly Wins UK Approval for Oral Weight-Loss Pill Foundayo as Biotech Sector Sees Wave of Catalysts
Eli Lilly's oral weight-loss pill orforglipron, branded Foundayo, secured its first European regulatory approval in Britain on August 10, extending the drug's commercial footprint beyond…